Abstract
This review gives an overview of various neuroimmunological diseases in terms of incidence and prevalence rates, age and sex distribution, and the frequency of subtypes, if applicable. The disorders selected for review are inflammatory muscle disorders (polymyositis, dermatomyositis and inclusion body myositis), myasthenia gravis, immune-mediated polyneuropathies (Guillain-Barré syndrome, chronic polyneuritis and vasculitic neuropathies), and multiple sclerosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aragones JM, Bolibar I, Bonfill X, Bufill E, Mummany A, Alonso F, Illa I (2003) Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 60(6):1024–1026
Arnason BG, Soliven B (1993) Acute inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds) Peripheral neuropathy. WB, Saunders, Philadelphia, pp 1437–1497
Badrising UA, Maat-Schiemann M, van Duinen SG et al. (2000) Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 55:1385–1387
Busby M, Donaghy M (2003) Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J Neurol 250:714–724
Cheng Q, Jiang GX, Fredrikson S (2000) Incidence of Guillain-Barré syndrome in Sweden 1996. Eur J Neurol 7:11–16
Collins MP, Periquet MI (2004) Non-systemic vasculitic neuropathy. Curr Opin Neurol 17:587–598
Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221–1231
Dalakas MC (2004) Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 17:561–567
Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982
Drachman DB (1994) Myasthenia gravis. N Engl J Med 330:1797–1810
Dyck PJ, Benstead TJ, Conn DL et al. (1987) Nonsystemic vasculitic neuropathy. Brain 110:843–853
Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology (1997) A prospective study on the incidence and prognosis of Guillain-Barré syndrome in Emilia-Romagna region, Italy (1992–1993). Neurology 48:214–221
Flachenecker P, Zettl UK (2005) Epidemiologie. In: Schmidt RM, Hoffmann F (eds) Multiple Sklerose. Urban and Fischer, München, pp 9–15
Flachenecker P, Zettl UK, Götze U, Haas J, Schimrigk S, Elias W, Pette M, Eulitz M, Hennig M, Bertram J, Hollweck R, Neiss A, Daumer M, Pitschnau-Michel D, Rieckmann P (2005) MS-Register in Deutschland—Design und erste Ergebnisse der Pilotphase. Nervenarzt 76:967–975
Govoni V, Granieri E (2001) Epidemiology of the Guillain-Barre syndrome. Curr Opin Neurol 14:605–613
Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT (2004) Guillain-Barre syndrome following influenza vaccination. JAMA 292:2478–2481
Hartung HP, Kieseier BC, Kiefer R (2001) Progress in Guillain-Barré syndrome. Curr Opin Neurol 14:597–604
Hartung HP, Pollard JD, Harvey GK, Toyka KV (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome—Part I Muscle Nerve 18:137–153
Hein T, Hopfenmüller W (2000) Hochrechnung der Zahl an Multiple Sklerose erkrankten Patienten in Deutschland. Nervenarzt 71:288–294
Hohlfeld R, Wekerle H (1994) The thymus in myasthenia gravis. Neurol Clin 12:331–342
Hovi T, Stenvik M (2000) Surveillance of patients with acute flaccid paralysis in Finland: report of a pilot study. Bull World Health Organ 78:298–304
Hunder GG, Arend WP, Bloch DA et al. (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33:1065–1067
Jennette JC, Falk RJ,Andrassy K et al. (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192
Jiang GX, Cheng Q, Link H, de Pedro-Cuesta J (1997) Epidemiological features of Guillain-Barré syndrome in Sweden, 1978–1993. J Neurol Neurosurg Psychiatry 62:447–453
Kaida K, Kusunoki S, Kamakura K et al. (2000) Guillain-Barré syndrome with antibody to a ganglioside, Nacetylgalactosaminyl GD1a. Brain 123:116–124
Keegan BM, Noseworthy JH (2002) Multiple sclerosis. Annu Rev Med 53:285–302
Kissel JT (2001) Vasculitic neuropathies. In: Gilman S (ed) MedLink Neurology. MedLink Corporation, San Diego
Kurtzke JF (1993) Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 6:382–427
Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, Schonberger LB, Chen RT (1998) The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 339:1797–1802
Léger JM, Behin A (2005) Multifocal motor neuropathy. Curr Opin Neurol 18:567–573
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911
Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F (2003) Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 998:413–423
Martyn C (1991) The epidemiology of multiple sclerosis. In: Matthews WB (ed) McAlpines’s multiple sclerosis. Churchill Livingstone, New York, pp 3–40
Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M (2003) Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000. Neurology 61:1373–1377
Meyer-Rienecker H, Buddenhagen F (1988) Incidence of multiple sclerosis: a periodic or stable phenomenon. J Neurol 235:241–244
Mygland A, Monstad P (2001) Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 8:157–165
Nobile-Orazio E (2004) IgM paraproteinaemic neuropathies. Curr Opin Neurol 17:599–605
Oldflors A, Lindberg C (2005) Diagnosis, pathogenesis and treatment of inclusion body myositis. Curr Opin Neurol 18:497–503
Olney RK, Lewis RA, Putnam TD, Campellone RV (2003) Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 27:117–121
Palace J, Vincent A, Beeson D (2001) Myasthenia gravis: diagnostic and management dilemmas. Curr Opin Neurol 14:583–589
Phillips BA, Zilko PJ, Mastaglia FL (2000) Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 23:970–972
Phillips LH (2004) The epidemiology of myasthenia gravis. Semin Neurol 24:17–20
Pinching AJ, Peters DK, Newsom Davis J (1976) Remission of myasthenia gravis following plasma exchange. Lancet 2:1373–1376
Poser CM (1994) The epidemiology of multiple sclerosis: a general overview. Ann Neurol 36(Suppl 2):S180–S193
Potagas C, Dellatolas G, Tavernarakis A, Molari H, Mourtzouhou P, Koutra H, Matikas N, Balakas N (2004) Myasthenia gravis: changes observed in a 30-years retrospective clinical study of a hospital-based population. J Neurol 251:116–117
Rees JH, Soudain SE, Gregson NA, Hughes RA (1995) Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 333:1374–1379
Saperstein DS, Katz JS, Amato AA, Barohn RJ (2001) Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 24:311–324
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al. (1979) Guillain-Barré syndrome following vaccination in the national influenza immunization program, United States, 1976–1977. Am J Epidemiol 110:105
Sommer C, Heuss D, Schlotter-Weigel B, Engelhardt A, Reinhold-Keller E (2003) Diagnostik und Therapie der vaskulitischen Neuropathien und Neuropathien bei Kollagenosen. In: Diener HC, für die Kommission „Leitlinien“ der Deutschen Gesellschaft für Neurologie (eds) Leitlinien für Diagnostik und Therapie in der Neurologie. Georg Thieme Verlag, Stuttgart New York, pp 263–273
Teixeira A, Cherin P, Demoule A et al. (2005) Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromuscul Disord 15:32–39
Toyka KV, Drachman DB, Pestronk A, Kao I (1975) Myasthenia gravis: passive transfer from man to mouse. Science 190:397–399
van der Meulen MFG, Bonner M, Hoogendijk JE et al. (2003) Polymyositis: a diagnostic entity reconsidered. Neurology 61:316–321
van Doorn PA, Ruts L (2004) Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol 17:607–613
van Koningsveld R, van Doorn PA, Schmitz PIM et al. (2000) Mild forms of Guillain-Barré syndrome in an epidemiological survey in the Netherlands. Neurology 54:620–625
Viala K, Renie T, Maisonobe T et al. (2004) Follow-up and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 127:2010–2017
Voermans NC, Vaneker M, Hengstman GJ et al. (2004) Primary respiratory failure in inclusion body myositis. Neurology 63:2191–2192
Weinshenker BG, Bass B, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 112:133–146
Willison HJ, Veitch J, Paterson G, Kennedy PGE (1993) Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 56:204–206
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s00415-008-0881-z.
Rights and permissions
About this article
Cite this article
Flachenecker, P. Epidemiology of neuroimmunological diseases. J Neurol 253 (Suppl 5), v2–v8 (2006). https://doi.org/10.1007/s00415-006-5001-3
Issue Date:
DOI: https://doi.org/10.1007/s00415-006-5001-3